Key result
ARBs demonstrate antiproteinuric effects similar to ACE inhibitors but require long-term studies confirming clinical renoprotection.
Why the study?
Whether angiotensin II type 1 receptor antagonists have the same renoprotective effect as angiotensin-converting enzyme inhibitors in progressive renal diseases remains ill defined.
Do Angiotensin II type 1 receptor antagonists provide similar antiproteinuric and renoprotective effects as ACE inhibitors in progressive renal disease?
Do Angiotensin II type 1 receptor antagonists provide similar antiproteinuric and renoprotective effects as ACE inhibitors in progressive renal disease?
This review highlights that while ARBs show promising antiproteinuric effects comparable to ACE inhibitors, long-term studies are needed to confirm their renoprotective benefits in humans.
No takes yet. Share an insight, caveat, or question.
May support ACEI renoprotection in proteinuric kidney disease; leaves open clinical translation from animal models.
Perico et al. (1998) conducted a review in Hypertension and progressive renal disease. Angiotensin II type 1 receptor antagonists vs. Angiotensin-converting enzyme inhibitors was evaluated on Antiproteinuric effects and renoprotection. Angiotensin II type 1 receptor antagonists demonstrate consistent antiproteinuric effects similar to ACE inhibitors, though long-term studies are needed to confirm clinical renoprotection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: